GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, an MIT spinout that has now raised at least $166m to date.
SQZ Biotechnologies, a US-based cellular vaccine developer spun out of Massachusetts Institute of Technology, closed a $65m series D round on Monday that included GV and Illumina Ventures, respective investment subsidiaries of internet technology conglomerate Alphabet and genomics technology producer Illumina.
The round was led by Singaporean government-owned investment firm Temasek and also featured NanoDimension, Polaris Partners, an unnamed US-based fund and JDRF T1D Fund, which is managed by diabetes-focused charity JRDF.
Founded in 2013, SQZ is working…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
